Contested
Where the evidence disagrees. v2 surfaces disagreement through
three primitives — preregistered colliders,
polled predictions that hit conflict,
and the challenge-edge graph (refutes / contradicts). All three feed this page.
collider Open colliders
all colliders →Two sides, one objective resolution criterion, real stakes.
- PROCEED-AD or comparable senescence-targeted clinical readout (target 2027): does combined senolytic depletion (e.g. dasatinib + quercetin) outperform sustained SASP-modulation (e.g. JAK inhibition) on cognitive endpoints in MCI/early-AD over a 24-month window?
- smoke test of SPEC-022 PR 22.2
- smoke test of SPEC-022 PR 22.2
- smoke test of SPEC-022 PR 22.2
edge Challenge-edge leaderboard
Artifacts ranked by incoming challenge-edge count
(refutes / contradicts / contradicts_v2). Counts are independent of vote/fund
signals so quiet-but-disputed claims still surface.
No artifacts in this filter have accumulated refutes/contradicts edges.
Lower min_challenges or drop type/domain.